rs2219594

Variant summary

Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_000059.4(BRCA2):​c.4681C>A​(p.His1561Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000492 in 1,613,942 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0026 ( 3 hom., cov: 33)
Exomes 𝑓: 0.00027 ( 0 hom. )

Consequence

BRCA2
NM_000059.4 missense

Scores

1
15

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:23O:1

Conservation

PhyloP100: -0.0170
Variant links:
Genes affected
BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.009818286).
BP6
Variant 13-32339036-C-A is Benign according to our data. Variant chr13-32339036-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 51695.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=6, not_provided=1, Benign=11, Uncertain_significance=1}. Variant chr13-32339036-C-A is described in Lovd as [Benign]. Variant chr13-32339036-C-A is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00263 (400/152216) while in subpopulation AFR AF= 0.00929 (386/41542). AF 95% confidence interval is 0.00853. There are 3 homozygotes in gnomad4. There are 183 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 3 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
BRCA2NM_000059.4 linkuse as main transcriptc.4681C>A p.His1561Asn missense_variant 11/27 ENST00000380152.8 NP_000050.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
BRCA2ENST00000380152.8 linkuse as main transcriptc.4681C>A p.His1561Asn missense_variant 11/275 NM_000059.4 ENSP00000369497 A2

Frequencies

GnomAD3 genomes
AF:
0.00264
AC:
401
AN:
152098
Hom.:
3
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00934
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000590
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00191
GnomAD3 exomes
AF:
0.000637
AC:
160
AN:
251048
Hom.:
1
AF XY:
0.000309
AC XY:
42
AN XY:
135748
show subpopulations
Gnomad AFR exome
AF:
0.00901
Gnomad AMR exome
AF:
0.000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000881
Gnomad OTH exome
AF:
0.000327
GnomAD4 exome
AF:
0.000270
AC:
394
AN:
1461726
Hom.:
0
Cov.:
47
AF XY:
0.000213
AC XY:
155
AN XY:
727162
show subpopulations
Gnomad4 AFR exome
AF:
0.00986
Gnomad4 AMR exome
AF:
0.000313
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000812
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000450
Gnomad4 OTH exome
AF:
0.000613
GnomAD4 genome
AF:
0.00263
AC:
400
AN:
152216
Hom.:
3
Cov.:
33
AF XY:
0.00246
AC XY:
183
AN XY:
74420
show subpopulations
Gnomad4 AFR
AF:
0.00929
Gnomad4 AMR
AF:
0.000589
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000208
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00189
Alfa
AF:
0.000489
Hom.:
0
Bravo
AF:
0.00296
ESP6500AA
AF:
0.00976
AC:
43
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000725
AC:
88
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.00
EpiControl
AF:
0.0000593

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:23Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Benign:5Other:1
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesMar 20, 2017- -
not provided, no classification providedreference populationITMISep 19, 2013- -
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-- -
Benign, no assertion criteria providedclinical testingClinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute-- -
Likely benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoDec 08, 2021- -
Benign, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Aug 04, 2014- -
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:1Benign:4
Benign, criteria provided, single submitterclinical testingMichigan Medical Genetics Laboratories, University of MichiganApr 21, 2016- -
Benign, no assertion criteria providedclinical testingSharing Clinical Reports Project (SCRP)May 01, 2012- -
Uncertain significance, no assertion criteria providedclinical testingBreast Cancer Information Core (BIC) (BRCA2)May 29, 2002- -
Benign, criteria provided, single submitterliterature onlyCounsylMar 18, 2014- -
Likely benign, criteria provided, single submitterclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical CenterSep 21, 2015- -
not provided Benign:4
Likely benign, no assertion criteria providedclinical testingLaboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)-- -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 29, 2023- -
Likely benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Likely benign, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, University Medical Center Utrecht-- -
Hereditary cancer-predisposing syndrome Benign:4
Likely benign, criteria provided, single submittercurationUniversity of Washington Department of Laboratory Medicine, University of WashingtonMar 23, 2023Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
Benign, criteria provided, single submitterclinical testingAmbry GeneticsNov 19, 2014This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Likely benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthMar 12, 2015- -
Benign, criteria provided, single submittercurationSema4, Sema4Jul 08, 2020- -
Hereditary breast ovarian cancer syndrome Benign:4
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Benign, criteria provided, single submitterclinical testingNational Health Laboratory Service, Universitas Academic Hospital and University of the Free StateApr 19, 2022- -
Likely benign, criteria provided, single submitterresearchGenetics Program, Instituto Nacional de CancerNov 01, 2021- -
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 28, 2014- -
Breast neoplasm Uncertain:1
Uncertain significance, criteria provided, single submitterresearchA.C.Camargo Cancer Center / LGBM, A.C.Camargo Cancer Center-- -
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioMay 25, 2022- -
Familial cancer of breast Benign:1
Benign, criteria provided, single submitterclinical testingBaylor GeneticsFeb 23, 2017- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.083
BayesDel_addAF
Benign
-0.49
T
BayesDel_noAF
Benign
-0.47
CADD
Benign
5.1
DANN
Benign
0.70
Eigen
Benign
-0.65
Eigen_PC
Benign
-0.69
FATHMM_MKL
Benign
0.059
N
M_CAP
Benign
0.057
D
MetaRNN
Benign
0.0098
T;T
MetaSVM
Benign
-0.91
T
MutationTaster
Benign
1.0
N;N
PrimateAI
Benign
0.33
T
PROVEAN
Pathogenic
-4.8
D;D
REVEL
Benign
0.14
Sift
Benign
0.20
T;T
Sift4G
Benign
1.0
T;T
Vest4
0.38
MVP
0.86
MPC
0.032
ClinPred
0.027
T
GERP RS
2.5
gMVP
0.16

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs2219594; hg19: chr13-32913173; COSMIC: COSV66453039; API